Compare Cassava Sciences Inc (FLNA) vs Kingsoft Cloud Holdings Limited (KC) Price & Performance

Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).

The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.

Kingsoft Cloud (KC) trades at $9.23 with no recent price movement. The stock shows bearish technical signals with support at $8-9 levels. Fundamentally, while revenue grew to $9.56B in 2025, the company reported a net loss of $936M with negative profit margins. Recent Q2 2026 results beat expectations with 30.8% revenue growth and improved gross margins driven by AI cloud services expansion.

Analyst consensus remains positive with 70% buy ratings and 60.3% upside potential, but technical indicators suggest caution. Key risks include ongoing profitability challenges and competitive pressures in China's cloud market. The AI partnership with Xiaomi provides growth catalyst potential, though execution risks persist.